Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 2/20 | 0.45 |
| ▸ | HCAR2 | Q8TDS4 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TPMT | P51580 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GABRP | O00591 | 1/20 | 0.38 |
| ▸ | GABRD | O14764 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.38 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.38 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.38 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.38 |
| ▸ | GABRE | P78334 | 1/20 | 0.38 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL882970 | 0.79 | APLNR (0.50) | APLNRHCAR2MAPTRAB9AALDH1A1 | |
| SCHEMBL5047396 | 0.77 | APLNR (0.48) | APLNRMAPTRAB9ASMN1; SMN2 | |
| SCHEMBL24787182 | 0.76 | CA12 (0.36) | HCAR2MAPTALDH1A1GABRPGABRD | |
| SCHEMBL3705899 | 0.76 | ALDH1A1 (0.54) | HCAR2MAPTALDH1A1GABRPGABRD | |
| SCHEMBL18520707 | 0.74 | TPMT (0.39) | HCAR2ALDH1A1TPMTGABRPGABRD | |
| SCHEMBL20929049 | 0.74 | HCAR2 (0.34) | HCAR2MAPTALDH1A1GABRPGABRD | |
| SCHEMBL10328694 | 0.74 | HCAR2 (0.41) | APLNRHCAR2KDM4EKMO | |
| SCHEMBL3695695 | 0.74 | GABRP (0.41) | HCAR2MAPTALDH1A1GABRPGABRD | |
| SCHEMBL6873117 | 0.74 | HCAR2 (0.37) | HCAR2ALDH1A1GABRPGABRDGABRA1 | |
| SCHEMBL361106 | 0.74 | KDM4E (0.52) | HCAR2ALDH1A1SMN1; SMN2GABRPGABRD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110167944-B | Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors | 联合疗法公司 | 2024-08-23 | — | — | CN | claimed |
| WO-2025124460-A1 | TRICYCLIC FUSED HETEROCYCLIC PDE3/4 DUAL INHIBITOR, AND PREPARATION AND USE THEREFOR | 石家庄以岭药业股份有限公司 | 2025-06-19 | — | — | WO | disclosed |
| CN-120136869-A | Tricyclic fused heterocyclic PDE3/4 dual inhibitor and preparation method and application thereof | 石家庄以岭药业股份有限公司 | 2025-06-13 | — | — | CN | disclosed |
| EP-3541804-B1 | CYCLOALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC (US) | 2025-01-22 | — | — | EP | disclosed |
| EP-3541802-B1 | ALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC (US) | 2025-01-01 | — | — | EP | disclosed |
| US-12180221-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-12-31 | — | — | US | disclosed |
| CN-110167944-B | Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors | 联合疗法公司 | 2024-08-23 | — | — | CN | disclosed |
| US-20240246960-A1 | 7-Morpholino-L,6-Naphthyridin-5-yl Derivatives and Pharmaceutical Compositions Thereof Useful as DNA-PK Inhibitor | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2024-07-25 | — | — | US | disclosed |
| US-20240239790-A1 | 7-Morpholino-1,6-Naphthyridin-5-yl Derivatives and Pharmaceutical Compositions Thereof Useful as DNA-PK Inhibitor | LIFEARC (GB) | 2024-07-18 | — | — | US | disclosed |
| WO-2024137329-A1 | METHODS FOR THE SYNTHESIS OF COMPLEMENT FACTOR D INHIBITORS AND INTERMEDIATES THEREOF | ALEXION PHARMACEUTICALS, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2014085490-A1 | CXCR7 ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2014-06-05 | — | — | WO | disclosed |
| WO-2013142269-A1 | IMIDAZOTRIAZINONE COMPOUNDS | ENVIVO PHARMACEUTICALS, INC. (US) | 2013-09-26 | — | — | WO | disclosed |
| WO-2013013817-A1 | SUBSTITUTED HETEROCYCLIC AZA DERIVATIVES | Grünenthal GmbH (DE) | 2013-01-31 | — | — | WO | disclosed |
| US-20120238751-A1 | TRICYCLIC GYRASE INHIBITORS | TRIUS THERAPEUTICS, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| US-20120238751-A1 | TRICYCLIC GYRASE INHIBITORS | TRIUS THERAPEUTICS, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| EP-2471787-A1 | New compounds | Boehringer Ingelheim International GmbH (DE) | 2012-07-04 | — | — | EP | disclosed |
| US-20110263565-A1 | COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
| US-20110263565-A1 | COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
| WO-2010012747-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-04 | — | — | WO | disclosed |
| EP-0444286-A1 | Sulphonylated pyrimidine carboxylic acid amides | BAYER AG (DE) | 1991-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239790-A1 | 7-Morpholino-1,6-Naphthyridin-5-yl Derivatives and Pharmaceutical Compositions Thereof Useful as DNA-PK Inhibitor | DCK, ERCC2, POLK | APLNR 3540/4885HCAR2 4349/4885MAPT 4288/4885 |
| US-20240246960-A1 | 7-Morpholino-L,6-Naphthyridin-5-yl Derivatives and Pharmaceutical Compositions Thereof Useful as DNA-PK Inhibitor | DCK, ERCC2, POLK | APLNR 3480/4885HCAR2 4379/4885MAPT 4225/4885 |
| US-20120238751-A1 | TRICYCLIC GYRASE INHIBITORS | TOP1, TOP2A, TOP2B | APLNR 4860/4885HCAR2 3804/4885MAPT 2765/4885 |
| US-20110263565-A1 | COMPOUNDS | MKI67, CCNA1, CCNT1 | APLNR 2268/4885HCAR2 2890/4885MAPT 3861/4885 |
| US-12180221-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | APLNR 2399/4885HCAR2 520/4885MAPT 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.